1.5900
07-February-25 15:45:00
15 minutes delayed
Stocks
-0.0300
-1.85%
Today's range
1.5500 - 1.6200
ISIN
N/A
Source
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 Sep 2024 07:30:00 By Nasdaq GlobeNewswire